Resverlogix (TSE:RVX) has released an update.
Resverlogix Corp., a Calgary-based biotech leader in epigenetics, has rescheduled its Annual and Special Meeting of Shareholders to July 31, 2024. Shareholders will receive a Notice of Meeting and be privy to a corporate update presentation at the event. The company is advancing its lead candidate, apabetalone, targeting cardiovascular disease and related conditions, and is collaborating with EVERSANA™ to expedite its launch in North America.
For further insights into TSE:RVX stock, check out TipRanks’ Stock Analysis page.
